Scientists May Have Found How Aggressive Prostate Cancer Resists Treatment

Key Points:

• Researchers at Fred Hutch Cancer Center have identified transfer RNA (tRNA) as a key molecular regulator influencing aggressive and drug-resistant forms of prostate cancer, offering a potential new target for treatment.
• The study, published in Nature, found that tRNA can modulate the synthesis of proteins critical for the effectiveness of certain prostate cancer drugs, potentially reversing drug resistance in cancer cells.
• This discovery suggests tRNA levels could serve as biomarkers for aggressive prostate cancer and that therapies increasing tRNA may prevent the cancer from becoming more resistant, though clinical studies are needed.
• Experts highlight the significance of this finding, as metastatic prostate cancer often becomes resistant to current treatments like androgen deprivation therapy, chemotherapy, and radioisotopes.
• Ongoing development of tRNA-based therapeutics by several companies may pave the way for novel treatments targeting drug-resistant prostate cancer in the future.